Johan Lund

Company: AQILION AB

Job title: Chief Scientific Officer

Seminars:

Interrogating the Safety & Efficacy Profile of JAK1 Selective Inhibitors in Inflammatory Disorders to Apply Learnings to the Skin 11:30 am

What can we learn from advances of JAK inhibitors in alternative indications? Investigating mechanistic data and early clinical trial biomarker data to assess efficacy and safety of JAK1 inhibitors Navigating clinical decision making and illuminating opportunities for indication expansion in inflammatory disordersRead more

day: Pre-Conference Workshop Day